Lecture Notes

**Lecture Coverage:**
- Factors Affecting Treatment Decisions
- Surgery
- Radiotherapy
- Chemotherapy
- Targeted Therapy
- Combination Therapy

---
#### **Factors Affecting Treatment Decisions**
**Necessity of Treatment**

| Tumor Type | Invasiveness & Metastasis Potential |
| :--------: | ----------------------------------- |
|  Indolent  | Low                                 |
| Low-Grade  | Medium (Can be removed)             |
| High-Grade | High                                |

**Method of Treatment**
- Cancer Staging
	- Stage 0/I/II: Local Invasion
	- Stage III: Lymph / Neighboring Tissue Invasion
	- Stage IV: Distant Metastasis
- Histological Diagnosis
	- Tumor Subtype
	- Tumor Differentiation
	- Tumor Aggressiveness (Primary / Recurrent / Metastatic)
- Tumor-related Mutations
- Tumor Microenvironment
	- Hot: High T-Cell Infiltration → Inflammation
	- Cold: Low T-Cell Infiltration → Hard to treat with immunotherapy


#### **Surgery**
- Resection
	- Primary Tumors exhibiting local invasion
	- Neighboring Tissues & Lymph Nodes

**Types of Surgery**

|     Surgery Type     | Description                                         |
| :------------------: | --------------------------------------------------- |
| Preventative Surgery | Colon Polyp Removcal                                |
|  Diagnostic Surgery  | Biopsy for Cancer Staging / Lab Tests               |
|   Curative Surgery   | Complete Tumor Removal (Sometimes with Lymph Nodes) |
|  Palliative Surgery  | Surgery to Relieve Discomfort only                  |


#### **Radiotherapy**
- Radiation → cancer cell DNA damage
	- → DNA Repair Mechanism Activation → Cell Cycle Arrest
	- → Double Strand break → Genomic Instability & Apoptosis

**Radiation Sources**

| Radiation Sources | Effectiveness | Precision |   Cost    | Availability |
| :---------------: | :-----------: | :-------: | :-------: | :----------: |
|       X-Ray       |      Low      |    Low    |    Low    |     High     |
|      Proton       |      Low      |   High    |   High    |     Low      |
|    Carbon Ions    |     High      |   High    | Very High |   Very Low   |
- X-Ray based approaches can be improved by focusing radiation dose to tumor area
	- <abbr Title="Intensity-Modulated Radiation Therapy">IMRT</abbr>: Determine Dose Pattern through CT / MRI & Computer Calculation
		- Precise Radiation Doses at Different Angles
	- Gamma Knife Radiosurgery
		- For Small / Medium Brain Tumors


#### **Chemotherapy**
- Induce DNA Damage to Tumor Cells
	- Delivered Systemically

**Chemotherapy Drug Types**

|         Drug Type          |         <          | Mechanism                                                                                                                                      | Examples                                      |
| :------------------------: | :----------------: | :--------------------------------------------------------------------------------------------------------------------------------------------- | :-------------------------------------------- |
|    <br>Alkylating Drugs    |         <          | Form Interstand Crosslinks in DNA <br>→ Prevent Daughter Strand Separation in DNA Replication<br>→ Mitosis if unrepaired                       | G: Nitrogen Mustard<br>AG: Platinum Compounds |
|    <br>Antimetabolites     |    Antifolates     | Inhibit Thymidine Biosynthesis                                                                                                                 | 5-FU & MTX                                    |
|             ^              | Nucleotide Analogs | Stop strand elongation                                                                                                                         | Gemcitabine                                   |
| <br>Antitumor Antibiotics  |         <          | <abbr Title="Responsible for DNA Unwinding">Topoisomerase I / II</abbr> Inhibitors<br>→ Double strand break at Replication Fork<br>→ Apoptosis | Anthracyclines<br>Camptothesin<br>Etoposide   |
| <br><br>Mitotic Inhibitors |  Vinca Alkaloids   | Bind to Mitotic Spindle Microtubules<br>→ ↓ Polymerization                                                                                     |                                               |
|             ^              |      Taxanes       | ↑ Tubulin Polymerization<br>→ Freeze Cell in Metaphase                                                                                         |                                               |

**Limitations of Chemotherapy**
- Not universally effective
- Toxic to normal cells (Hair loss, Skin sensitivity)
- Drug Resistance
	- ↓ Drug Bioavailability
	- ↓ Apoptosis & ↑ Metabolic Detoxification
		- ∵ Mutation / Over-expression of Gene Targets
		- ∵ ↑ DNA Repair Capacity


#### **Targeted Therapy**
|         Target         |                                     Drug Type                                     | Mechanism                                                                   | Examples                                                                         |
| :--------------------: | :-------------------------------------------------------------------------------: | :-------------------------------------------------------------------------- | :------------------------------------------------------------------------------- |
|      <br>Hormones      |                                  Anti-Estrogens                                   | Estrogen Antagonists                                                        |                                                                                  |
|           ^            |                                  Anti-Androgens                                   | Androgen Antagonists                                                        |                                                                                  |
|  <br>Signal Pathways   |          <br><abbr Title="Receptor Tyrosine Kinase">RTK</abbr> Inhbitors          | Block Ligand Binding → No Dimerization                                      | Cetuxi<font color="yellow">mab</font> & Trastuzu<font color="yellow">mab</font>  |
|           ^            |                                         ^                                         | Binds to ATP binding Pocket → No Kinase                                     | Small Molecule Inhibitors                                                        |
|           ^            |                               Downstream Inhbitors                                | Multiple Targets (RAS, RAF, ERK, MEK)                                       | Small Molecule Inhibitors                                                        |
|  <br>Mutant Proteins   |                                    Promiscuous                                    | ↓ Specificity but ↑ Complete Inhibition                                     | Sorafe<font color="yellow">nib</font> (VEGFR1-3 + Kinases)                       |
|           ^            |                                     Selective                                     | ↓ Off Target Effects                                                        | Erloti<font color="yellow">nib</font> & Gefiti<font color="yellow">nib</font>    |
|           ^            |                                 Mutant-Selective                                  | ↑ Specificity & Therapeutic Index                                           | Vemurafe<font color="yellow">nib</font> (BRAF<sup>V600E</sup>)                   |
| Overexpressed Proteins |                             Antibody-Drug Conjugates                              | Target-Specific Antibodies + Cytotoxic Drugs                                |                                                                                  |
| Pro-Angiogenic Factors | <abbr Title="Vascular Endothelial Growth Factor Receptor">VEGFR</abbr> Inhibitors | ↓ Angiogenesis                                                              | Sorafenib & Bevacizumab                                                          |
| Cell Cycle Inhibitors  |                                         <                                         | CDK4/6 Inhibitors → G1 Cell Cycle Arrest                                    | Palbo<font color="yellow">ciclib</font> & Ribo<font color="yellow">ciclib</font> |
| Metabolism Inhibitors  |                                         <                                         | Mutant IDH1/2 Inhibitor (Produces <abbr Title="Oncometabolite">2-HG</abbr>) | Ivo<font color="yellow">sidenib</font> & Ena<font color="yellow">sidenib</sub>   |
|   Apoptosis Inducers   |                                         <                                         | BCL-2 Inhibitor → Apoptosis                                                 | Venetoclax                                                                       |

**Advantages & Disadvantages of Targeted Therapy**
- Advantages:
	- ↑ Specificity
	- ↓ Toxicity
- Disadvantages
	- ↓ Coverage
	- Tumor Heterogeneity & Adaptive Evolution → Drug Resistance
		- Overexpression & Mutations → Overcome Blockade
		- Upstream & Downstream Activation → Bypass Blockade

**Role of Diagnostics in Targeted Therapy**
- Additional mutations may grant tumors immunity to target therapies
	- E.g. Cetuximab in KRAS-Mutation (30-40% of <abbr Title="Colorectal Cancer">CRC</abbr>) Patients


#### **Combination Therapy**
- Chemotherapy + Targeted Therapy / Immune Checkpoint Therapy


**Advantages & Disadvantages of Combination Therapy**
- Advantages:
	- Synergism → ↑ Efficacy in Eliminating All Cancer Cells
	- ↓ Drug Resistance
- Disadvantages:
	- Potential Toxicity